{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:36:34Z","timestamp":1787502994806,"version":"build-2736575974"},"reference-count":39,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,2,1]]},"abstract":"<jats:p>OBJECTIVE. The purpose of this work was to evaluate therapy for patent ductus arteriosus as a risk factor for death or neurodevelopmental impairment at 18 to 22 months, bronchopulmonary dysplasia, or necrotizing enterocolitis in extremely low birth weight infants.<\/jats:p>\n                  <jats:p>METHODS. We studied infants in the National Institute of Child Health and Human Development Neonatal Research Network Generic Data Base born between 2000 and 2004 at 23 to 28 weeks' gestation and at &amp;lt;1000-g birth weight with patent ductus arteriosus. Patent ductus arteriosus therapy was evaluated as a risk factor for outcomes in bivariable and multivariable analyses.<\/jats:p>\n                  <jats:p>RESULTS. Treatment for subjects with patent ductus arteriosus (n = 2838) included 403 receiving supportive treatment only, 1525 treated with indomethacin only, 775 with indomethacin followed by secondary surgical closure, and 135 treated with primary surgery. Patients who received supportive therapy for patent ductus arteriosus did not differ from subjects treated with indomethacin only for any of the outcomes of interest. Compared with indomethacin treatment only, patients undergoing primary or secondary surgery were smaller and more premature. When compared with indomethacin alone, primary surgery was associated with increased adjusted odds for neurodevelopmental impairment and bronchopulmonary dysplasia in multivariable logistic regression. Secondary surgical closure was associated with increased odds for neurodevelopmental impairment and increased adjusted odds for bronchopulmonary dysplasia but decreased adjusted odds for death. Risk of necrotizing enterocolitis did not differ among treatments. Indomethacin prophylaxis did not significantly modify these results.<\/jats:p>\n                  <jats:p>CONCLUSIONS. Our results suggest that infants treated with primary or secondary surgery for patent ductus arteriosus may be at increased risk for poor short- and long-term outcomes compared with those treated with indomethacin. Prophylaxis with indomethacin in the first 24 hours of life did not modify the subsequent outcomes of patent ductus arteriosus therapy.<\/jats:p>","DOI":"10.1542\/peds.2007-2781","type":"journal-article","created":{"date-parts":[[2009,1,26]],"date-time":"2009-01-26T07:23:44Z","timestamp":1232954624000},"page":"674-681","source":"Crossref","is-referenced-by-count":146,"title":["Patent Ductus Arteriosus Therapy: Impact on Neonatal and 18-Month Outcome"],"prefix":"10.1542","volume":"123","author":[{"given":"Juliette C.","family":"Madan","sequence":"first","affiliation":[{"name":"Division of Newborn Medicine, Department of Pediatrics, Floating Hospital for Children, Tufts Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Kendrick","sequence":"additional","affiliation":[{"name":"StatEpi Division, RTI International, Research Triangle Park, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James I.","family":"Hagadorn","sequence":"additional","affiliation":[{"name":"Division of Neonatology, Department of Pediatrics, Connecticut Children's Medical Center, University of Connecticut School of Medicine, Hartford, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Ivan D.","family":"Frantz","sequence":"additional","affiliation":[{"name":"Division of Newborn Medicine, Department of Pediatrics, Floating Hospital for Children, Tufts Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the National Institute of Child Health and Human Development Neonatal Research Network","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2009,2,1]]},"reference":[{"key":"2021120822570852400_R1","doi-asserted-by":"crossref","unstructured":"Fanaroff AA, Stoll BJ, Wright LL, et al. Trends in neonatal morbidity and mortality for very low birth weight infants. Am J Obstet Gynecol.\u20082007;196(2):147.e1\u2013147.e8","DOI":"10.1016\/j.ajog.2006.09.014"},{"key":"2021120822570852400_R2","doi-asserted-by":"crossref","unstructured":"Lee SK, McMillan DD, Ohlsson A, et al. Variations in practice and outcomes in the Canadian NICU network 1996\u20131997. Pediatrics.\u20082000;106(5):1070\u20131079","DOI":"10.1542\/peds.106.5.1070"},{"key":"2021120822570852400_R3","doi-asserted-by":"crossref","unstructured":"Itabashi K, Ohno T, Nishida, H. Indomethacin responsiveness of patent ductus arteriosus and renal abnormalities in preterm infants treated with indomethacin. J Pediatr.\u20082003;143(2):203\u2013207","DOI":"10.1067\/S0022-3476(03)00303-2"},{"key":"2021120822570852400_R4","doi-asserted-by":"crossref","unstructured":"Gersony WM, Peckham GJ, Ellison RC, Miettinen OS, Nadas AS. Effects of indomethacin in premature infants with PDA: results of a national collaborative study. J Pediatr.\u20081983;102(6):895\u2013906","DOI":"10.1016\/S0022-3476(83)80022-5"},{"key":"2021120822570852400_R5","doi-asserted-by":"crossref","unstructured":"Grosfeld JL, Chaet M, Molinari F, Engle W, Engum SA, West KW. Increased risk of NEC in premature infants with PDA treated with indomethacin. Ann Surg.\u20081996;224(3):350\u2013355","DOI":"10.1097\/00000658-199609000-00011"},{"key":"2021120822570852400_R6","doi-asserted-by":"crossref","unstructured":"Cotton RB, Stahlman MT, Kovar I, Catterton WZ. Medical management of small preterm infants with symptomatic patent ductus arteriosus. J Pediatr.\u20081979;92(3):467\u2013473","DOI":"10.1016\/S0022-3476(78)80451-X"},{"key":"2021120822570852400_R7","doi-asserted-by":"crossref","unstructured":"Satur CR, Walker DR, Dickinson DF. Day case surgical closure of PDA in preterm infants: a 10 year review. Arch Dis Child.\u20081991;66(4):477\u2013480","DOI":"10.1136\/adc.66.4.477"},{"key":"2021120822570852400_R8","doi-asserted-by":"crossref","unstructured":"Narayanan M, Cooper B, Weiss H, Clyman RI. Prophylactic indomethacin: factors determining permanent ductus arteriosus closure. J Pediatr.\u20082000;136(3):330\u2013337","DOI":"10.1067\/mpd.2000.103414"},{"key":"2021120822570852400_R9","doi-asserted-by":"crossref","unstructured":"Little DC, Pratt TC, Blalock SE, Krauss DR, Cooney DR, Custer MD. PDA in micropreemies and full term infants: the relative merits of surgical closure versus indomethacin treatment. J Pediatr Surg.\u20082003;38(3):492\u2013496","DOI":"10.1053\/jpsu.2003.50086"},{"key":"2021120822570852400_R10","doi-asserted-by":"crossref","unstructured":"Quinn D, Cooper B, Clyman RI. Factors associated with permanent closure of the ductus arteriosus: a role for prolonged indomethacin therapy. Pediatrics.\u20082002;110(1). Available at: www.pediatrics.org\/cgi\/content\/full\/110\/1\/e10","DOI":"10.1542\/peds.110.1.e10"},{"key":"2021120822570852400_R11","doi-asserted-by":"crossref","unstructured":"Sperandio M, Beedgen B, Feneberg R, et al. Effectiveness and side effects of an escalating, stepwise approach to indomethacin treatment for symptomatic PDA in premature infants below 33 weeks of gestation. Pediatrics.\u20082005;116(6):1361\u20131366","DOI":"10.1542\/peds.2005-0293"},{"key":"2021120822570852400_R12","doi-asserted-by":"crossref","unstructured":"Koch J, Hensley G, Roy L, Brown S, Ramaciotti Cl, Rosenfeld C. Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less. Pediatrics.\u20082006;117(4):1113\u20131121","DOI":"10.1542\/peds.2005-1528"},{"key":"2021120822570852400_R13","doi-asserted-by":"crossref","unstructured":"Jaillard S, Larrue B, Rakza T, Magnenant E, Warembourg H, Storme L. Consequences of delayed surgical closure of PDA in very premature infants. Ann Thorac Surg.\u20082006;81(1):231\u2013234","DOI":"10.1016\/j.athoracsur.2005.03.141"},{"key":"2021120822570852400_R14","doi-asserted-by":"crossref","unstructured":"Madan J, Fiascone J, Griffith J, Balasubramanian V, Hagadorn J. Predictors of successful ductal closure, necrotizing enterocolitis, and focal intestinal perforation in very low birth weight infants treated with indomethacin or surgical ligation for patent ductus arteriosus. Neonatology.\u20082008;94(1):45\u201351","DOI":"10.1159\/000113058"},{"key":"2021120822570852400_R15","doi-asserted-by":"crossref","unstructured":"Keller RL, Clyman RI. Persistent Doppler flow predicts lack of response to multiple courses of indomethacin in premature infants with recurrent patent ductus arteriosus. Pediatrics.\u20082003;112(3 pt 1):583\u2013587","DOI":"10.1542\/peds.112.3.583"},{"key":"2021120822570852400_R16","doi-asserted-by":"crossref","unstructured":"Mavroudis C, Cook LN, Fleischaker JW, et al. Management of PDA in preterm infants; indomethacin versus surgical closure. Ann Thorac Surg.\u20081983;36(5):561\u2013566","DOI":"10.1016\/S0003-4975(10)60686-8"},{"key":"2021120822570852400_R17","doi-asserted-by":"crossref","unstructured":"Malviya M, Ohlsson A, Shah S. Surgical versus medical therapy with cyclooxygenase inhibitors for symptomatic PDA in preterm infants. Cochrane Database Syst Rev.\u20082003;(3):CD003951","DOI":"10.1002\/14651858.CD003951"},{"key":"2021120822570852400_R18","doi-asserted-by":"crossref","unstructured":"O'Donovan DJ, Baetiong A, Adams K, et al. NEC and GI complications after indomethacin therapy and surgical closure in premature infants with PDA. J Perinatol.\u20082003;23(4):286\u2013290","DOI":"10.1038\/sj.jp.7210911"},{"key":"2021120822570852400_R19","doi-asserted-by":"crossref","unstructured":"Lee LC, Tillett A, Tulloh R, Yates R, Kelsall W. Outcome following PDA surgical closure in premature infants: a retrospective cohort analysis. BMC Pediatr.\u20082006;6:15","DOI":"10.1186\/1471-2431-6-15"},{"key":"2021120822570852400_R20","doi-asserted-by":"crossref","unstructured":"Laughon M, Bose C, Clark R. Treatment strategies to prevent or close a PDA in preterm infants and outcomes. J Perinatol.\u20082007;27(3):164\u2013170","DOI":"10.1038\/sj.jp.7211662"},{"key":"2021120822570852400_R21","doi-asserted-by":"crossref","unstructured":"Chorne N, Leonard C, Piecuch R, Clyman RI. PDA and its treatment as risk factors for neonatal and neurodevelopmental morbidity. Pediatrics.\u20082007;119(6):1165\u20131174","DOI":"10.1542\/peds.2006-3124"},{"key":"2021120822570852400_R22","doi-asserted-by":"crossref","unstructured":"Kabra NS, Schmidt B, Roberts RS, et al. Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms. J Pediatr.\u20082007;150(3):229\u2013234, 29","DOI":"10.1016\/j.jpeds.2006.11.039"},{"key":"2021120822570852400_R23","doi-asserted-by":"crossref","unstructured":"Vanhaesebrouck S, Zonnenberg I, Vandervoort P, Bruneel E, Van Hoestenberghe MR, Theyskens C. Conservative treatment for PDA in the preterm. Arch Dis Child Fetal Neonatal Ed.\u20082007;92(4):F244\u2013F247","DOI":"10.1136\/adc.2006.104596"},{"key":"2021120822570852400_R24","doi-asserted-by":"crossref","unstructured":"Bose CL, Laughon MM. PDA: lack of evidence for common treatments. Arch Dis Child Fetal Neonatal Ed.\u20082007;92(6):F498\u2013F502","DOI":"10.1136\/adc.2005.092734"},{"key":"2021120822570852400_R25","doi-asserted-by":"crossref","unstructured":"Fowlie PW, Davis PG. Prophylactic indomethacin for preterm infants: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed.\u20082003;88(6):F464\u2013F466","DOI":"10.1136\/fn.88.6.F464"},{"key":"2021120822570852400_R26","doi-asserted-by":"crossref","unstructured":"Schmidt B, Davis P, Moddemann D, et al. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight-infants. N Engl J Med.\u20082001;344(26):1966\u20131972","DOI":"10.1056\/NEJM200106283442602"},{"key":"2021120822570852400_R27","doi-asserted-by":"crossref","unstructured":"Ment LR, Vohr B, Oh W, et al. Neurodevelopmental outcome at 36 months' corrected age of preterm infants in the Multicenter Indomethacin Intraventricular Hemorrhage Prevention Trial. Pediatrics.\u20081996;98(4 pt 1):714\u2013718","DOI":"10.1542\/peds.98.4.714"},{"key":"2021120822570852400_R28","doi-asserted-by":"crossref","unstructured":"Bell MJ, Ternberg JL, Keating JP, Marshall R, Barton L, Brotherton T. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg.\u20081978;187(1):1\u20137","DOI":"10.1097\/00000658-197801000-00001"},{"key":"2021120822570852400_R29","doi-asserted-by":"crossref","unstructured":"Clyman RI, Chorne N. Patent ductus arteriosus: evidence for and against treatment. J Pediatr.\u20082007;150(3):216\u2013219","DOI":"10.1016\/j.jpeds.2006.12.048"},{"key":"2021120822570852400_R30","doi-asserted-by":"crossref","unstructured":"Doyle LW; Victorian Infant Collaborative Study Group. Outcome at 5 years of age of children 23 to 27 weeks' gestation: refining the prognosis. Pediatrics.\u20082001;108(1):134\u2013141","DOI":"10.1542\/peds.108.1.134"},{"key":"2021120822570852400_R31","doi-asserted-by":"crossref","unstructured":"Gonzales A, Sosenko IR, Chandar J, Hummler H, Claure N, Bancalari E. Influence of infection on PDA and chronic lung disease in premature infants weighing 1000 grams or less. J Pediatr.\u20081996;12:470\u2013478","DOI":"10.1016\/S0022-3476(96)70356-6"},{"key":"2021120822570852400_R32","doi-asserted-by":"crossref","unstructured":"Merritt TA, Harris JP, Roghmann K, et al. Early closure of PDA in VLBW infants: a controlled trial. J Pediatr.\u20081981;99(2):281\u2013286","DOI":"10.1016\/S0022-3476(81)80479-9"},{"key":"2021120822570852400_R33","doi-asserted-by":"crossref","unstructured":"Rojas MA, Gonzales A, Bancalari E, Claure N, Poole C, Silva-Neto G. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. J Pediatr.\u20081995;126(4):605\u2013610","DOI":"10.1016\/S0022-3476(95)70362-4"},{"key":"2021120822570852400_R34","doi-asserted-by":"crossref","unstructured":"Zanardo V, Trevisanuto D, Dani C, et al. \u201cSilent\u201d PDA and BPD in VLBW infants. J Perinat Med.\u20081995;23(6):493\u2013499","DOI":"10.1515\/jpme.1995.23.6.493"},{"key":"2021120822570852400_R35","doi-asserted-by":"crossref","unstructured":"Watterberg K. Anti-inflammatory therapy in the NICU: present and future. Semin Fetal Neonatal Med.\u20082006;11(5):378\u2013384","DOI":"10.1016\/j.siny.2006.02.006"},{"key":"2021120822570852400_R36","doi-asserted-by":"crossref","unstructured":"Laughon MM, Simmons MA, Bose CL. Patency of the ductus arteriosus in the premature infant: is it pathologic? Should it be treated?Curr Opin Pediatr.\u20082004;16(2):146\u2013151","DOI":"10.1097\/00008480-200404000-00005"},{"key":"2021120822570852400_R37","doi-asserted-by":"crossref","unstructured":"Ment LR, Oh W, Ehrenkranz RA, et al. Low-dose indomethacin and prevention of intraventricular hemorrhage: a multicenter randomized trial. Pediatrics.\u20081994;93(4):542\u2013550","DOI":"10.1542\/peds.93.4.543"},{"key":"2021120822570852400_R38","doi-asserted-by":"crossref","unstructured":"Cordero L, Nankervis CA, Delooze D, Giannone PJ. Indomethacin prophylaxis or expectant treatment of patent ductus arteriosus in extremely low birth weight infants?J Perinatol.\u20082007;27(3):158\u2013163","DOI":"10.1038\/sj.jp.7211659"},{"key":"2021120822570852400_R39","doi-asserted-by":"crossref","unstructured":"Ment LR, Vohr B, Allan W, et al. Outcome of children in the indomethacin intraventricular hemorrhage prevention trial. Pediatrics.\u20082000;105(3 pt 1):485\u2013491","DOI":"10.1542\/peds.105.3.485"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/123\/2\/674\/1124727\/zpe00209000674.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/123\/2\/674\/1124727\/zpe00209000674.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T15:14:20Z","timestamp":1684854860000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/123\/2\/674\/69380\/Patent-Ductus-Arteriosus-Therapy-Impact-on"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,1]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2009,2,1]]},"published-print":{"date-parts":[[2009,2,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2007-2781","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,1]]}}}